Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Lipocine Inc.
  6. News
  7. Summary
    LPCN   US53630X1046

LIPOCINE INC.

(LPCN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lipocine: Q3 Earnings Snapshot

11/10/2021 | 08:12am EST

SALT LAKE CITY (AP) _ Lipocine Inc. (LPCN) on Wednesday reported a loss of $3.1 million in its third quarter.

The Salt Lake City-based company said it had a loss of 3 cents per share.

The specialty pharmaceutical company posted revenue of $55,000 in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LPCN at https://www.zacks.com/ap/LPCN

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about LIPOCINE INC.
01/21Lipocine Chief Financial Officer is Retiring
MT
01/21LIPOCINE INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/14LIPOCINE INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan..
AQ
01/05Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
PR
01/04LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021LIPOCINE : ANNOUNCES patient dosed in its Phase 2 Study with LPCN 1148 for management of l..
PU
2021LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Lipocine Commences Dosing in Phase 2 Study of Liver Cirrhosis Drug
MT
2021Lipocine announces patient dosed in its phase 2 study with lpcn 1148 for management of ..
PR
2021Lipocine Inc. Announces Patient Dosed in its Phase 2 Study with LPCN 1148 for Managemen..
CI
More news
Analyst Recommendations on LIPOCINE INC.
More recommendations
Financials (USD)
Sales 2021 3,75 M - -
Net income 2021 -14,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,57x
Yield 2021 -
Capitalization 78,7 M 78,7 M -
Capi. / Sales 2021 21,0x
Capi. / Sales 2022 12,8x
Nbr of Employees 13
Free-Float 97,5%
Chart LIPOCINE INC.
Duration : Period :
Lipocine Inc. Technical Analysis Chart | LPCN | US53630X1046 | MarketScreener
Technical analysis trends LIPOCINE INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,89 $
Average target price 3,75 $
Spread / Average Target 321%
EPS Revisions
Managers and Directors
Mahesh V. Patel President, Chief Executive Officer & Director
Morgan R. Brown Chief Financial Officer & Executive Vice President
Anthony DelConte Chief Medical Director
Richard Dana Ono Independent Director
Stephen Anthony Hill Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LIPOCINE INC.-10.09%79
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624